Comparative Pharmacology
Head-to-head clinical analysis: CECLOR CD versus CEPHAPIRIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CECLOR CD versus CEPHAPIRIN SODIUM.
CECLOR CD vs CEPHAPIRIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefaclor, a second-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
250-500 mg orally every 8 hours; extended-release form (CECLOR CD) 375-750 mg orally every 12 hours.
500 mg to 1 g IM or IV every 6 hours.
None Documented
None Documented
Terminal elimination half-life: ~0.6-0.9 hours (prolonged in renal impairment)
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Renal: ~80% unchanged; biliary/fecal: ~20%
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic